Troubleshooting Report - CZE and CE-SDS the Discussion Continues
CZE and CE-SDS the Discussion Continues
Workshop facilitators: Tim Blanc1, Cari Sänger-van de Griend2
Scribes: Nathan Lacher3, David Michels4, Zoran Sosic5
1. Eli Lilly and Company, Branchburg, NY, USA
2. Kantisto BV, Baarn, the Netherlands
3. Pfizer, Inc., Chesterfield, MO, USA
4. Genentech, a Member of the Roche Group, South San Francisco, CA, USA
5.Biogen, Cambridge, MA, USA
This publication reflects the views of the author and should not be construed to represent FDA's views or policies.
Workshop facilitators: Tim Blanc1, Cari Sänger-van de Griend2
Scribes: Nathan Lacher3, David Michels4, Zoran Sosic5
1. Eli Lilly and Company, Branchburg, NY, USA
2. Kantisto BV, Baarn, the Netherlands
3. Pfizer, Inc., Chesterfield, MO, USA
4. Genentech, a Member of the Roche Group, South San Francisco, CA, USA
5.Biogen, Cambridge, MA, USA
This publication reflects the views of the author and should not be construed to represent FDA's views or policies.